Through its clinical trials, Capricor Therapeutics is actively engaged in the development of novel therapeutics to prevent and treat cardiac and other serious medical conditions.
Capricor completed the HOPE-2 clinical trial for Capricor’s lead investigational therapy, CAP-1002.
HOPEPHASE I/II enrollment complete
The Halt cardiomyOPathy progrEssion in Duchenne (HOPE) Phase I/II trial will evaluate CAP-1002 in patients with Duchenne muscular dystrophy associated cardiomyopathy.
ALLSTARPHASE I completed
PHASE II enrollment complete
The ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial is a Phase I/II trial evaluating the safety and efficacy of lead therapeutic candidate, CAP-1002 – Capricor’s allogeneic, off-the-shelf, cardiosphere-derived cell product.
DYNAMICPHASE I completed
The Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells (DYNAMIC) Phase I trial evaluated CAP-1002 in patients with advanced heart failure.
CADUCEUSPHASE I completed
The prospective, randomized Intracoronary CArdiosphere-Derived aUtologous Stem CElls to reverse ventricUlar dySfunction (CADUCEUS) Phase I trial was a proof-of-concept study that evaluated the safety and efficacy of Capricor’s investigational, autologous cardiosphere-derived cell (CDC) product, CAP-1001.